Home
Statistics
Acknowledgment
Enquire
Keyword Search
Complex Search
Segment Search
Peptide Mapping
Browse On
Mode of delivery
Animal model
Origin/Source
Peptide Length
Similarity
BLAST Search
Smith-Waterman
General
Help or Guide
Data Submission
Curators
Developers
Contact Us
Browse result page of B3Pdb
The total number entries retrieved from this search are
318
, scroll left/right for detailed information.
B3pdbID
PEPTIDE NAME
PEPTIDE SEQUENCE (1-letter)
PEPTIDE SEQUENCE (3-letter)
N-TERMINAL MODIFICATION
C-TERMINAL MODIFICATION
CHEMICAL MODIFICATION
PEPTIDE LENGTH
PEPTIDE CONFORMATION
PEPTIDE NATURE
SOURCE/ORIGIN OF PEPTIDE
SMILES
CELL LINE
In vitro
CONCENTRATION
In vitro
METHOD
In vitro
RESULT
ANIMAL MODEL
In vivo
CONCENTRATION
In vivo
MODE OF DELIVERY
In vivo
METHOD
In vivo
RESULT
ACTION
TRANSPORT TYPE
SUBCELLULAR LOCALISATION
COMBINATION
PHYSICAL CONDITION
RESPONSE
RESULT
LABEL
PMID
b3pdb_0001
Mtfpep
DSSHAFTLDELR
AspSerSerHisAlaPheThrLeuAspGluLeuArg
NA
Polyethylene glycol (PEG)4 linker
NA
12
Linear
NA
Melanotransferrin
N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CCC(=O)O)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)O
NA
NA
NA
NA
Mice
2 MTfpep per NIP228 antibody
Intravenous
3D confocal fluorescence microscopy
Two times greater fractional fluorescence was measured in the brain parenchyma.
It delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates
Transcytosis
Surface of normal brain endothelial cells, the main constituent of the BBB, and is able to cross thr
Successfully delivers therapeutic amounts of an an
Neuropathic pain
Stability/half life
5.5 days
NA
29845881
b3pdb_0007
D-T7
HRPYIAHC
HisArgProTyrIleAlaHisCys
NA
Cysteine on C-terminal
NA
7
Linear
NA
Chemically synthesized
N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CS)C(=O)O
bEnd.3 and c6 cells
NA
Confocal microscopy
It crosses the BBB.
Mice
PTX-1.7 mg/kg, CD-3.6 mg/kg
Intravenous
NA
NA
D-T7 Peptide Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Ant
NA
NA
Combined with Cediranib and Paclitaxel.
Glioma
Stability/half life
3.31-fold higher than saline
NA
30525386
b3pdb_0008
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.3 micromolar
NA
30824786
b3pdb_0009
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
1.6 ± 0.9micromolar
NA
30824786
b3pdb_0010
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
1.6 ± 0.8 micromolar
NA
30824786
b3pdb_0011
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Alone
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0012
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0013
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0014
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0015
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.9 micromolar
NA
30824786
b3pdb_0016
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.7 micromolar
NA
30824786
b3pdb_0017
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.4 micromolar
NA
30824786
b3pdb_0018
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.3 micromolar
NA
30824786
b3pdb_0019
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.3 micromolar
NA
30824786
b3pdb_0020
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0021
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.3 micromolar
NA
30824786
b3pdb_0022
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0023
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.4 micromolar
NA
30824786
b3pdb_0024
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0025
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0026
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.4 micromolar
NA
30824786
b3pdb_0027
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
50.0 ± 10.2 micromolar
NA
30824786
b3pdb_0028
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 5.1 micromolar
NA
30824786
b3pdb_0029
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0030
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.7 micromolar
NA
30824786
b3pdb_0031
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.7 micromolar
NA
30824786
b3pdb_0032
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 2.2 micromolar
NA
30824786
b3pdb_0033
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0034
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.5 micromolar
NA
30824786
b3pdb_0035
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 5.1 micromolar
NA
30824786
b3pdb_0036
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.9 micromolar
NA
30824786
b3pdb_0037
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.9 micromolar
NA
30824786
b3pdb_0047
C-TN-APNPs
CAQK
CysAlaGlnLys
NA
NA
NA
4
Linear
NA
Chemically synthesized
N[C@@]([H])(CS)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCCN)C(=O)O
hCMEC/D3 and NHA cells
NA
TEM imaging
Responsive to thrombin cleavage, reduced the cytotoxicity of Tat-NR2B9c, and increased BBB permeabil
C57BL6 mice
NA
Intravenous
Dynamic light scattering
Better circulation time, better targeting ability and penetrating efficiency to the injured brain, a
Treatment reduced the injury size
NA
NA
Combined with Tat-NR2B9c
Traumatic brain injury
NA
NA
NA
31213815
b3pdb_0048
CC-TN-APNPs
CCAQK
CysCysAlaGlnLys
NA
NA
NA
5
Linear
NA
Chemically synthesized
N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)N[C@@]([H])(CCCCN)C(=O)O
hCMEC/D3 and NHA cells
NA
TEM imaging
Responsive to thrombin cleavage, reduced the cytotoxicity of Tat-NR2B9c, and increased BBB permeabil
C57BL6 mice
NA
Intravenous
Dynamic light scattering
Better circulation time, better targeting ability and penetrating efficiency to the injured brain, a
Treatment reduced the injury size
NA
NA
Combined with Tat-NR2B9c
Traumatic brain injury
NA
NA
NA
31213815
b3pdb_0049
gH625Cys
HGLASTLTRWAHYNALIRAF
HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPhe
Acetylaed at N-terminal
Cys-CONH2 group is attached at C-terminal
NA
21
Linear
NA
Chemically synthesized
N[C@@]([H])(CC1=CN=C-N1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O
BMECs
5 micromolar
Fluorescence microscopy
Liposomes preparations were non-toxic for the endothelial cells and improves the transfer of liposom
Mouse
NA
Intravenous
Fluorescence microscopy
gH625 ameliorates the efficiency of liposomes to deliver. PACAP
gH625-liposomes represent a promising strategy to deliver therapeutic agents to CNS and to provide a
NA
NA
Comined with liposome
NA
NA
NA
NA
31235716
b3pdb_0050
Deltorphan
YAFDVVG
Tyr-(D)Ala-Phe-Asp-Val-Val-Gly-NH2
NA
Amide group is attached
NA
7
Linear
NA
Chemically synthesized
N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(C(C)C)C(=O)N[C@@]([H])(C(C)C)C(=O)NCC(=O)O
NA
NA
NA
NA
C57BL6 mice
NA
Intravenous
Confocal microscopy
Presence of engineered nano particles within the brain parenchyma with particular focus on hippocamp
Opioid-derived peptides featured by specific helix-like conformation as possible ligands to engineer
NA
CNS parenchyma
Comined
NA
NA
NA
NA
32479916
b3pdb_0051
SLS
SLSHSPQ
SerLeuSerHisSerProGln
NA
NA
NA
7
Cyclic
Neutral
Chemically synthesized
N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(CO)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCC(=O)N)C(=O)O
hCMEC/D3 cell monolayers
200000 cells per well
Confocal microscopy
It promoted phage permeation across the hCMEC/D3 cell monolayer.
Mice
NA
Intravenous
Plaque formation assay
Cyclic SLS peptide facilitated phage permeation across the mouse BBB in vivo
BBB-permeable cyclic SLS heptapeptide for brain delivery of macromolecules via macropinocytosis and
Macropinocytosis
Brain parenchyma
Combined with M13 phage
NA
NA
NA
NA
32135226
b3pdb_0080
BVDO2
DmtNmeAFS-NH2
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
5 mg/Kg
Intravenous
Hot water tail flick test
70% maximum possible effect after 5 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0081
BVDO2
DmtNmeAFS-NH3
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
5 mg/Kg
Intravenous
Hot water tail flick test
100% maximum possible effect after 15 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0082
BVDO2
DmtNmeAFS-NH4
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
5 mg/Kg
Intravenous
Hot water tail flick test
100% maximum possible effect after 30 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0083
BVDO2
DmtNmeAFS-NH5
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
5 mg/Kg
Intravenous
Hot water tail flick test
100% maximum possible effect after 60 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0084
BVDO2
DmtNmeAFS-NH6
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
5 mg/Kg
Intravenous
Hot water tail flick test
100% maximum possible effect after 120 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0085
BVDO2
DmtNmeAFS-NH7
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
1 mg/Kg
Intravenous
Hot water tail flick test
40% maximum possible effect after 5 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0086
BVDO2
DmtNmeAFS-NH8
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
1 mg/Kg
Intravenous
Hot water tail flick test
80% maximum possible effect after 15 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0087
BVDO2
DmtNmeAFS-NH9
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
1 mg/Kg
Intravenous
Hot water tail flick test
80% maximum possible effect after 30 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0088
BVDO2
DmtNmeAFS-NH10
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
1 mg/Kg
Intravenous
Hot water tail flick test
90% maximum possible effect after 60 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0089
BVDO2
DmtNmeAFS-NH11
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
1 mg/Kg
Intravenous
Hot water tail flick test
100% maximum possible effect after 120 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0090
BVDO2
DmtNmeAFS-NH12
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
0.5 mg/Kg
Intravenous
Hot water tail flick test
10% maximum possible effect after 5 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0091
BVDO2
DmtNmeAFS-NH13
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
0.5 mg/Kg
Intravenous
Hot water tail flick test
40% maximum possible effect after 15 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
b3pdb_0092
BVDO2
DmtNmeAFS-NH14
H-Dmt-Nme-D-Ala-Phe-Ser-NH2
Methylation
Amidation
NA
4
Tetrapeptide
Cationic
NA
NA
NA
NA
NA
NA
C57BL6 mice
0.5 mg/Kg
Intravenous
Hot water tail flick test
70% maximum possible effect after 30 minutes
Cross BBB and shows morphine like action with analgesic effects
NA
NA
NA
NA
NA
NA
NA
22289619
previous
1
2
3
4
5
6
7
next
IIITD/CB
Raghava's Group
IMTECH
CellPPDMOD
